Log in

Company updateMoneycontrol

Buy Natco Pharma: target of Rs 1065: ICICI Securities

Positive+39

GreyOak summary

ICICI Securities upgraded Natco Pharma to a BUY rating with a target price of Rs 1,065. The firm noted that Q2FY27 performance exceeded expectations despite the loss of gRevlimid exclusivity, driven by a 32.7% sequential jump in formulations sales and an 80% surge in Brazil sales.

What it affects

Source

Read the original at Moneycontrol

More Natco Pharma news

All Natco Pharma news →

We use cookies

Essential cookies keep GreyOak secure and functional. Optional cookies help improve your experience and platform performance. You can update your preferences anytime.

Cookie Policy